GlassScriptPhysician profile
Cindy Kaufman
NPI 1861459919
$14,547.30
in general payments reported to CMS, 2019-2025
11 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,423 · 2021: $53.12 · 2022: $388 · 2023: $250 · 2024: $244 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,118.58 | 2019-2022 | |
| Medtronic Minimed, INC. | $1,655.49 | 2019 | |
| Amgen INC. | $977.18 | 2019-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.41 | 2019-2023 | Jardiance |
| Radius Health, INC. | $129.30 | 2020 | |
| Lilly USA, LLC | $121.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $116.81 | 2019-2022 | |
| Novo Nordisk INC | $45.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $14.10 | 2019 | |
| Medtronic, INC. | $13.68 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.